Peter Lamb - Exelixis EVP
| EXEL Stock | USD 36.36 0.66 1.78% |
EVP
Dr. Peter Lamb, Ph.D. is Executive Vice President Scientific Strategy, Chief Scientific Officer of the Company. He has served as Executive Vice President, Scientific Strategy and Chief Scientific Officer since February 2016. Previously, he served as Executive Vice President, Discovery Research and Chief Scientific Officer from September 2009 to February 2016, as Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until September 2009, as Vice President, Discovery Pharmacology from December 2003 until January 2007 and as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003. Prior to joining Exelixis, from June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, a pharmaceutical company, most recently serving as Director of Transcription Research since 2016.
| Age | 63 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 |
| Phone | 650 837 7000 |
| Web | https://www.exelixis.com |
Exelixis Management Efficiency
The company has return on total asset (ROA) of 0.1464 % which means that it generated a profit of $0.1464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2313 %, meaning that it created $0.2313 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.09. The value of Return On Capital Employed is expected to slide to 0.13. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Return On Tangible Assets will most likely fall to 0.09.Exelixis currently holds 190.82 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Exelixis has a current ratio of 5.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Exelixis' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 2 records | EVP Age | ||
| Neil Almstead | PTC Therapeutics | 58 | |
| Mark Boulding | PTC Therapeutics | 63 | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.15 |
Exelixis Leadership Team
Elected by the shareholders, the Exelixis' board of directors comprises two types of representatives: Exelixis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exelixis. The board's role is to monitor Exelixis' management team and ensure that shareholders' interests are well served. Exelixis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exelixis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Laura Dillard, Executive Resources | ||
| Tony Redmond, Senior Resources | ||
| Susan Hubbard, Executive Vice President - Public Affairs and Investor Relations | ||
| Gregg Bernier, VP Marketing | ||
| William MD, Senior Affairs | ||
| Amy MD, Product VP | ||
| Christopher Senner, CFO, Executive Vice President | ||
| Michael Morrissey, CEO and President and Director | ||
| Patrick MBA, Executive Commercial | ||
| Dana Aftab, Executive Officer | ||
| Jeffrey JD, Executive Counsel | ||
| Stefan Krauss, VP Development | ||
| Anne MD, Senior Safety | ||
| Stelios Papadopoulos, Chairman and Member of Audit Committee | ||
| Andrew Peters, Senior Strategy | ||
| MBA MBA, Ex Commercial | ||
| Peter Lamb, Chief Scientific Officer and Executive VP of Discovery Research |
Exelixis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exelixis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 9.33 B | ||||
| Shares Outstanding | 279.88 M | ||||
| Shares Owned By Insiders | 1.83 % | ||||
| Shares Owned By Institutions | 92.21 % | ||||
| Number Of Shares Shorted | 16.15 M | ||||
| Price To Earning | 48.17 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.754 | Earnings Share 1.76 | Revenue Per Share | Quarterly Revenue Growth 0.182 | Return On Assets |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.